Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10124355 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL10124356 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL10124379 | 0.90 | PIK3CB (0.46) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL10124700 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL10124321 | 0.88 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL16308128 | 0.86 | PIK3CB (0.47) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL16504203 | 0.85 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL16308241 | 0.83 | PIK3CB (0.55) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL15008819 | 0.83 | PIK3CB (0.58) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL3592039 | 0.82 | PIK3CB (0.58) | PIK3CDPIK3CBPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PIK3CD 7/4885PIK3CB 13/4885SMN1; SMN2 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.